Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Work In Process (2021 - 2023)

Kiniksa Pharmaceuticals International's Work In Process history spans 3 years, with the latest figure at $18.3 million for Q4 2023.

  • For Q4 2023, Work In Process rose 189.26% year-over-year to $18.3 million; the TTM value through Dec 2023 reached $18.3 million, up 189.26%, while the annual FY2023 figure was $18.3 million, 189.26% up from the prior year.
  • Work In Process reached $18.3 million in Q4 2023 per KNSA's latest filing, up from $13.4 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $18.3 million in Q4 2023 to a low of $148000.0 in Q1 2022.
  • Average Work In Process over 3 years is $8.3 million, with a median of $6.5 million recorded in 2022.
  • The largest YoY upside for Work In Process was 9033.11% in 2023 against a maximum downside of 189.26% in 2023.
  • A 3-year view of Work In Process shows it stood at $4.2 million in 2021, then surged by 50.9% to $6.3 million in 2022, then surged by 189.26% to $18.3 million in 2023.
  • Per Business Quant, the three most recent readings for KNSA's Work In Process are $18.3 million (Q4 2023), $13.4 million (Q3 2023), and $6.6 million (Q2 2023).